Nilotinib in accelerated phase chronic myelogenous leukemia (CML-AP) patients with imatinib-resistance or -intolerance: Update of a phase II study

被引：0
|
作者：
le Coutre, P.
Giles, F. J.
Apperley, J.
Ottmann, O. G.
Larson, R. A.
Haque, A.
Gallagher, N.
Rosti, G.
Cortes, J. E.
Kantarjian, H. M.
机构：
[1] Humboldt Univ, D-10099 Berlin, Germany
[2] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA
[3] Univ London Imperial Coll Sci Technol & Med, Hammersmith Hosp, London, England
[4] Med Klin III, Frankfurt, Germany
[5] Univ Chicago Hosp, Chicago, IL 60637 USA
[6] Novartis Pharmaceut, E Hanover, NJ USA
[7] Orsola Malpighi Univ, Bologna, Italy
[8] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2008年 / 26卷 / 15期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
7050
引用
收藏
页数：1
相关论文
共 50 条
  • [31] Correlation of different responses to imatinib on survival of patients (pts) with chronic myelogenous leukemia (CML) in accelerated (AP) and blast phase (BP).
    Aoki, E
    Kantarjian, H
    O'Brien, S
    Rios, MB
    Ravandi, F
    Verstovsek, S
    Garcia-Manero, G
    Shan, JQ
    Cortes, J
    BLOOD, 2005, 106 (11) : 321A - 321A
  • [32] Pharmacokinetic analysis of nilotinib in Chinese chronic myelogenous leukemia (CML) patients (pts) with imatinib-resistant or-intolerant disease in blast crisis (BC), accelerated phase (AP) or chronic phase (CP)
    Zhou, L.
    Hu, P.
    Meng, F.
    Wang, J.
    Wang, C.
    Hu, Z.
    Shen, Z.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [33] Resistance to imatinib among patients in chronic phase (CP) of chronic myelogenous leukemia (CML) in clinical practice
    Davis, C.
    Sanders, L.
    Hirji, I.
    Oliveria, S.
    Willey, V. J.
    Phillips, S.
    Yood, M. Ulcickas
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [34] Minimal cross-intolerance with nilotinib in patients with chronic myeloid leukemia in chronic or accelerated phase who are intolerant to imatinib
    Cortes, Jorge E.
    Hochhaus, Andreas
    le Coutre, Philipp D.
    Rosti, Gianantonio
    Pinilla-Ibarz, Javier
    Jabbour, Elias
    Gillis, Kathryn
    Woodman, Richard C.
    Blakesley, Rick E.
    Giles, Francis J.
    Kantarjian, Hagop M.
    Baccarani, Michele
    BLOOD, 2011, 117 (21) : 5600 - 5606
  • [35] The Clinical Impact of Time to Response in De Novo Accelerated Phase Chronic Myeloid Leukemia (CML-AP)
    Ohanian, Maro
    Kantarjian, Hagop M.
    Quintas-Cardama, Alfonso
    Jabbour, Elias J.
    Verstovsek, Srdan
    Borthakur, Gautam
    Ravandi, Farhad
    Garcia-Manero, Guillermo
    Ferrajoli, Alessandra
    Kadia, Tapan M.
    O'Brien, Susan
    Cortes, Jorge E.
    BLOOD, 2012, 120 (21)
  • [36] NILOTINIB IN CHRONIC MYELOID LEUKEMIA PATIENTS IN CHRONIC PHASE (CML-CP) WITH IMATINIB RESISTANCE OR INTOLERANCE: 24-MONTH FOLLOW-UP RESULTS OF A PHASE 2 STUDY
    Kantarjian, H.
    Giles, F. G.
    Bhalla, K. N. P.
    Pinilla, J.
    Larson, R. A.
    Gattermann, N.
    Ottmann, O. G.
    Wang, J.
    Gallagher, N. J.
    Baccarani, M.
    Le Coutre, P. D.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 254 - 255
  • [37] Nilotinib in Chronic Myeloid Leukemia Patients in Chronic Phase (CML-CP) with Imatinib Resistance or Intolerance: 2-Year Follow-up Results of a Phase 2 Study
    Kantarjian, Hagop M.
    Giles, Francis
    Bhalla, Kapil N.
    Larson, Richard A.
    Gattermann, Norbert
    Ottmann, Oliver G.
    Haque, Ariful
    Gallagher, Neil J.
    Baccarani, Michele
    le Coutre, Philipp D.
    BLOOD, 2008, 112 (11) : 1112 - 1112
  • [38] Frontline Tyrosine Kinase Inhibitors (TKI) As Initial Therapy for Patients with Chronic Myeloid Leukemia in Accelerated Phase (CML-AP)
    Ohanian, Maro
    Kantarjian, Hagop M.
    Quintas-Cardama, Alfonso
    O'Brien, Susan
    Verstovsek, Srdan
    Borthakur, Gautam
    Ravandi, Farhad
    Garcia-Manero, Guillermo
    Burton, Elizabeth M.
    Trinh, Long Xuan
    Ferrajoli, Alessandra
    Jabbour, Elias
    Kadia, Tapan
    Cortes, Jorge E.
    BLOOD, 2011, 118 (21) : 1614 - 1615
  • [39] Nilotinib in chronic myeloid leukaemia patients in chronic phase (CML-CP) with imatinib resistance or intolerance: follow-up results of a phase 2 study
    Clark, R.
    le Coutre, P.
    Giles, F. J.
    Hocchaus, A.
    Haque, A.
    Gallagher, N.
    Baccarani, M.
    Kantarjian, H. M.
    BRITISH JOURNAL OF HAEMATOLOGY, 2009, 145 : 40 - 40
  • [40] Safety and efficacy of nilotinib in routine clinical practice in patients with chronic myeloid leukemia in chronic or accelerated phase with resistance or intolerance to imatinib: results from the NOVEL study
    Kuo, Ching-Yuan
    Wang, Po-Nan
    Hwang, Wen-Li
    Tzeng, Cheng-Hwai
    Bai, Li-Yaun
    Tang, Jih-Luh
    Chang, Ming-Chih
    Lin, Sheng-Fung
    Chen, Tsai-Yun
    Chen, Yeu-Chin
    Tan, Tran-Der
    Hsieh, Chih-Yi
    Lin, Chinjune
    Lai, Clinton
    Miljkovic, Darko
    Chang, Cheng-Shyong
    THERAPEUTIC ADVANCES IN HEMATOLOGY, 2018, 9 (03) : 65 - 78
12345